I wonder why an association that is dealing with Allergies and Infectious Diseases is involved with developing chemical compounds to extract, or in their words "decorporate" radionuclides from the human body? Do they consider this form of contamination to be "infectious"?
Link: http://www.sciencedaily.com/releases/2006/09/060925163456.htm
While this may seem a legitamate concern; there are more profound motivations behind the develoment of these radionuclide chelating agents. Any country with nuclear development, uranium mining, or those against which "depleted uranium" bombs were used, should pay close attention to the development of these chelating agents.
The Departments of Energy and Defence, with the help of the Atomic Energy Commissions, have effectively contaminated the planet. I certainly don't just blame the USA, many other countries have been involved with this scenario. Canada has uranium mining operations and nuclear power (in the East - where they can keep it). Not to mention that we have allowed the British to control the "Suffield Base" in southern Alberta for development of biological and radiological weapons and counter-measures.
It is interesting to note what the doctors given "Project Biosheild" funding have been working on in the past;
Dr. Kenneth Raymond - anthrax, Fe(III)-templated Gd(III) self-assemblies, iron chelators
Dr. Scott Miller - radionuclide contamination, including experiments with beagles, and inhalation of Plutonium by workers
Dr. TG Levitskaia - fluoride, metal ion complexes
Dr. Raymond J. Bergeron - iron overload, chelator design (iron chelation from specific organs)
Dr. C. Timchalk - identification of biomarkers in blood, saliva and urine for Organophosphates, Lead and other heavy metals.
Link: http://www.sciencedaily.com/releases/2006/09/060925163456.htm
Project Bioshield: Researchers To Develop Anti-Radiation Treatments
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has issued five awards totaling $4 million to fund the development of products that eliminate radioactive materials from the human body following radiological or nuclear exposure. The awards, which were granted under Project Bioshield authorities, complement NIAID's other medical countermeasure efforts to create safe and effective products of this type.
"These new grants will help identify new drug candidates that could be acquired by the strategic national stockpile of medical countermeasures, which is available to the public after a terrorist or nuclear attack or accidental radioactive exposure," says NIAID Director Anthony S. Fauci, M.D.
In the event of an attack by a nuclear explosive device or radiological "dirty bomb," individuals potentially could inhale, ingest or absorb through their skin radioactive atoms called radionuclides. Depending on the type of radionuclide that a person is exposed to, the particles may be excreted from the body or enter bones, organs or other tissues, which could have significant adverse health consequences. Through an initiative announced in 2005, NIAID already is working to speed the development of a series of products that can bind (chelate) internally with the radionuclides and eliminate (decorporate) them from the body. Radionuclide decorporation products currently are available in the strategic national stockpile, but NIAID is focusing on expanding the product pool, creating new treatments capable of eliminating a wider range of radionuclides, developing products that can eliminate radioactive material faster and in greater amounts; and developing products in formulations that could be distributed more easily in a mass casualty situation.
NIAID has awarded five grants totaling up to $4 million to fund work for a period of 18 months. The following principal investigators and universities are the recipients of the grants:
* Raymond J. Bergeron, Ph.D., University of Florida, Gainesville, $1.0 million
* Tatiana G. Levitskaia, Ph.D., Pacific Northwest National Laboratory, Richland, WA, $725,000
* Scott C. Miller, Ph.D., University of Utah School of Medicine, Salt Lake City, $675,000
* Kenneth N. Raymond, Ph.D., University of California/Lawrence Berkeley National Laboratory, Berkeley, CA, $998,325
* Charles Timchalk, Ph.D., Pacific Northwest National Laboratory, Richland, WA, $599,747
"The goal of this new program is to accelerate the development of previously identified, promising compounds into effective products that could be licensed for use," says program officer Bert Maidment, Ph.D., associate director of product development in NIAID's Division of Allergy, Immunology and Transplantation.
NIAID issued the grants under authority provided by Project Bioshield, which was signed into law in 2004. Its enactment provided federal agencies with new tools to speed research on medical countermeasures to protect Americans against chemical, biological, radiological or nuclear attack.
While this may seem a legitamate concern; there are more profound motivations behind the develoment of these radionuclide chelating agents. Any country with nuclear development, uranium mining, or those against which "depleted uranium" bombs were used, should pay close attention to the development of these chelating agents.
The Departments of Energy and Defence, with the help of the Atomic Energy Commissions, have effectively contaminated the planet. I certainly don't just blame the USA, many other countries have been involved with this scenario. Canada has uranium mining operations and nuclear power (in the East - where they can keep it). Not to mention that we have allowed the British to control the "Suffield Base" in southern Alberta for development of biological and radiological weapons and counter-measures.
It is interesting to note what the doctors given "Project Biosheild" funding have been working on in the past;
Dr. Kenneth Raymond - anthrax, Fe(III)-templated Gd(III) self-assemblies, iron chelators
Dr. Scott Miller - radionuclide contamination, including experiments with beagles, and inhalation of Plutonium by workers
Dr. TG Levitskaia - fluoride, metal ion complexes
Dr. Raymond J. Bergeron - iron overload, chelator design (iron chelation from specific organs)
Dr. C. Timchalk - identification of biomarkers in blood, saliva and urine for Organophosphates, Lead and other heavy metals.